Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director representative entities reported a small equity award related to board compensation. A single grant of 421 restricted stock units (RSUs) of Common Stock was issued under Incyte's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees of $40,500 for Julian C. Baker’s board service. The RSUs are fully vested and are reported for each of 667, L.P. and Baker Brothers Life Sciences LP because each fund has an indirect pecuniary interest, while Baker Bros. Advisors LP has voting and dispositive power over the compensation shares pursuant to its policies.
HARRIGAN EDMUND reported acquisition or exercise transactions in this Form 4 filing.
INCYTE CORP director Edmund Harrigan received 269 shares of common stock as a fully vested restricted stock award. The shares were issued under Incyte’s Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees, pursuant to a pre-arranged Rule 10b5-1 election. After this grant, he directly holds 21,122 shares of common stock, which includes 2,518 shares issuable from previously reported restricted stock units that have not yet vested.
INCYTE CORP director Paul J. Clancy received 265 shares of common stock as a fully vested restricted share award. The grant was made under Incyte's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees, pursuant to an election intended to comply with Rule 10b5-1. Following this compensation-related acquisition, he holds 23,741 shares directly, including 2,518 shares of common stock issuable from previously reported restricted stock units that have not yet vested.
Incyte Corporation reported that Board member Susanne Schaffert has resigned from its Board of Directors. She notified the company on March 26, 2026, and her resignation will be effective April 15, 2026.
The company stated that her resignation was not due to any disagreement regarding its operations, policies, or practices, and the Board expressed appreciation for her service since 2022.
Incyte Corp Schedule 13G/A amendment reports that The Vanguard Group holds 0% of Incyte common stock, with 0 shares beneficially owned as of the filing. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries to report ownership separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
INCYTE CORP executive reports routine tax withholding share disposition. EVP, GM Dermatology US Matteo Trotta had 537 shares of common stock withheld at a price of $92.23 per share to cover tax obligations tied to previously granted restricted stock units. After this automatic withholding, he directly holds 14,882 common shares. Footnotes state that this figure includes 11,160 shares underlying restricted stock units that are not yet vested.
Incyte Corporation announced several executive leadership changes. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, adding broader enterprise-wide strategic and operational responsibilities while continuing to lead R&D. Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, continuing to oversee late-stage programs in Hematology, Oncology and Immunology and Global Medical Affairs.
Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, continuing to lead U.S. Oncology and taking on expanded responsibility for U.S. Immunology as these businesses are integrated into a single U.S. commercial organization. William J. Meury remains Chief Executive Officer and a member of the Board, while Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The filing states there were no changes to compensation arrangements for the impacted executives in connection with these title changes.
INCYTE CORP President, R&D Pablo J. Cagnoni exercised stock options and then sold shares in a routine liquidity transaction. He exercised options to acquire 7,166 shares of common stock at $61.18 per share and 11,501 shares at $64.25 per share, totaling 18,667 shares. On the same day, he sold 18,667 common shares at an average price of $94.24 per share. After these transactions, his reported direct ownership was 234,800 common shares, which the notes state includes 229,661 shares underlying previously reported unvested restricted and performance stock units.
INCY reports a Form 144 notice for the sale of 18,667 shares of Common Stock via a stock option exercise on 03/17/2026. The filing lists proceeds of 1,759,101.55 and shows prior sales in the past three months associated with Pablo Cagnoni. The transaction is reported through Morgan Stanley Smith Barney LLC as broker-dealer.
Incyte Corporation reported that on February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) injection in metastatic non-small cell lung cancer in combination with platinum-based chemotherapy.
The FDA’s letter cited regulatory compliance inspection findings at Catalent Indiana, the third-party fill-finish facility referenced in the application, as the sole approvability issue. The FDA did not raise concerns about Zynyz’s efficacy, safety data in NSCLC, or the third-party drug substance manufacturer. Incyte is working with the FDA and Catalent Indiana to address the letter and support a potential resubmission.